Holdings Co. Laboratories of America (NYSE:LH – Get Rating ) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $265.63.
Several analysts recently commented on the company. Morgan Stanley set their price objective on Laboratory Co. US dropped their price target from $300.00 to $290.00 and reissued an “overweight” rating for the company in a research note on Monday, October 31st. William Blair gave an “outperform” rating on shares of Laboratory Co. America confirmed in a report on Thursday, October 27. Mizuho raised its target price on Laboratory Co. The company lowered its stock from $296.00 to $250.00 and gave it a “buy” rating in report on Thursday, November 3. Citigroup Laboratory Co. American Downgraded from a “neutral” rating to a “neutral” rating and reduced their target price for the company from $275.00 to $250.00 in a report on Monday, December 12th. Finally, StockNews.com dropped Laboratory Co. Americas from a “buy” rating to a “hold” rating in a report on Monday, October 31st.
Laboratory Co. of America Stock Down 0.0%
LH stock opened at $231.65 on Monday. The stock’s 50 day simple moving average is $230.88 and its 200 day simple moving average is $23.56. Laboratory Co. America has a fifty-two week low of $200.32 and a fifty-two week high of $317.17. The company has a debt to equity ratio of 0.54, a quick ratio of 1.55 and a current ratio of 1.73. The company has a market cap of $20.52 billion, a P/E ratio of 12.35 and a beta of 1.07.
Laboratory Co. America (NYSE:LH – Get Rating ) last posted its quarterly earnings results on Thursday, October 27th. The medical research company reported $4.68 earnings per quarter, missing analysts’ consensus estimates of $4.71 by ($0.03). Laboratory Co. America had a return on equity of 20.33% and a net margin of 11.51%. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the company posted $6.82 earnings per share. The firm’s quarterly revenue was 11.2% compared to the same quarter last year. On average, research analysts expect that Laboratory Co. America’s 19.84 earnings per share for the current fiscal year.
Laboratory Co. of America Dividend Announcements
The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Thursday, November 17th were issued a $0.72 dividend. This is a $2.88 dividend on an annual basis and a 1.24% dividend yield. The ex-dividend date for this dividend was Wednesday, November 16th. Laboratory Co. America’s payout ratio is currently 15.36%.
Insider Transactions at Laboratory Co. of America
In related news, EVP Mark S. Schroeder sold 1,116 shares of the stock in a transaction dated Tuesday, November 8th. The stock sold for an average price of $232.67, for a total value of $259,659.72. Following the sale, the chief executive officer now owns 6,687 shares in the company, valued at $1,555,864.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.31% of the company’s stock.
Institutional investors invest in De Laboratorio Co. of America
Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. his position in the Laboratory Co. America raised 15.7% during the first quarter. BlackRock Inc. now owns 9,576,779 shares of the medical research company’s stock valued at $2,525,014,000 after buying an additional 1,302,369 shares in the last quarter. Financial for Lutheran has its headquarters in Laboratorio Co. American shares raised 3,972.0% during the quarter. Lutheran Financial now owns 895,433 shares of the medical research company’s stock valued at $209,854,000 after buying an additional 873,443 shares during the last quarter. JPMorgan Chase & Co. located in the Laboratory Co. America rose by 45.9% in the second quarter. JPMorgan Chase & Co. now owns 1,904,199 shares of the medical research company’s stock valued at $446,269,000 after buying an additional 598,645 shares in the last quarter. International Investment Management LLC bought a new position in shares of Laboratory Co. United States in the second quarter worth about $309,000. Finally, Nordea Investment Management AB increased its holdings in shares of Laboratory Co. America by 91.0% in the third quarter. Nordea Investment Management AB now owns 574,621 shares of the medical research company’s stock worth $199,843,000 after purchasing an additional 273,777 shares during the period. Hedge funds and other institutional investors own 89.70% of the company’s stock.
Laboratory Co. America Company Profile
Laboratory Holdings Corporation of America operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).
This moment-focused news report is generated from a collection of technology science and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before Co. If you’re looking at America’s lab, you want to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and recommends their stocks to clients every day. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and Co. The US laboratory was not on the list.
While Laboratory Co. Americas currently has a “Moderate Buy” rating among analysts, the top-rated analysts believe these five stocks are a better buy.
View Five Stocks Here